enGene Therapeutics (ENGNW) Stock: Why It's Up Today
Updated Oct 20, 2026, 1:16 PM ET · intraday price
- Trading at $0.17 as of 1:16 PM ET, +1.47% vs the prior close of $0.17.
- Volume 8.05K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)
ENGNW rises 1.5% to $0.17. Trading at $0.17 (intraday, 1:16 PM ET), +1.47% vs the prior close of $0.17. Day range $0.15–$0.17, opened at $2.10.
ENGNW daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 20, 2026 — ENGNW rises 1.5% to $0.17
- Trading at $0.17 (intraday, 1:16 PM ET), +1.47% vs the prior close of $0.17. Day range $0.15–$0.17, opened at $2.10.
- Volume was 8.05K shares, 0.6x its 50-day average of 12.99K.
- 52-week range $0.15–$0.17; the current price sits at 100% of that range, 0.1% below the 52-week high.
Oct 19, 2026 — ENGNW ends flat (-0.1%) to $0.17
- Closed at $0.17, -0.06% vs the prior close of $0.17. Day range $0.16–$0.17, opened at $2.10.
- Volume was 12.99K shares, 0.9x its 50-day average of 14.58K.
- 52-week range $0.13–$0.17; today's close sits at 90% of that range, 2.3% below the 52-week high.
ENGNW bull case vs bear case (from the data)
- Insiders made 4 open-market purchases in the last 12 months.
- Latest fiscal-year net income: loss of $117.30M.
- Share count up 30.9% in a year (dilution).
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
ENGNW latest news & SEC filings
Every SEC filing by or about ENGNW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Grossman William bought 5,102 shares at $1.97 (≈$10.05K) on Sep 22, 2026; now holds 5,102
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jul 31, 2026:
- Net income: -$32.50M (prior year -$28.99M) (loss widened vs Jul 31, 2025)
- Diluted EPS: -$0.47 (prior year -$0.57) (loss narrowed vs Jul 31, 2025)
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 22, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 22, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 22, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade ENGNW
- Last results release: Sep 8, 2026 (8-K Item 2.02). Previous ones: Jun 15, 2026, Mar 9, 2026, Dec 22, 2025. Based on that rhythm, the next report is likely around Dec 8, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.47% (largest 1.5%).
- Liquidity: about 10.52K shares (≈$1.81K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.17 vs a range of $0.15–$0.17 (100% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: William Grossman bought 5,102 shares on Sep 22, 2026.
- Latest filings: 10-Q Sep 8, 2026; 8-K Sep 8, 2026; 8-K Aug 11, 2026.
- Share count: 67.02M shares outstanding (Sep 2, 2026), +30.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ENGNW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | 2.10 | 0.17 | 0.15 | 0.17 | 8.05K |
| Oct 19, 2026 | 2.10 | 0.17 | 0.16 | 0.17 | 12.99K |
About enGene Therapeutics
enGene Therapeutics (ENGNW) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAINT-LAURENT. State of incorporation: Canada (Federal Level). Fiscal year ends October 31. SEC CIK 1980845.
ENGNW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Philip Astley-Sparke | Director | Jun 17, 2026 |
| Gerald A Brunk | Director | Jun 17, 2026 |
| Ronald Harold Wilfred Cooper | CEO & President | Feb 3, 2026 |
| Richard M Glickman | Director | Jun 17, 2026 |
| William Grossman | Interim Chief Medical Officer | Sep 24, 2026 |
| Paul J Hastings | Director | Jun 17, 2026 |
| Michael Thomas Heffernan | Director | Jun 17, 2026 |
| Wouter Joustra | Director | Jun 17, 2026 |
| Lota S. Zoth | Director | Jun 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Matthew Ross Boyd | Chief Regulatory Officer | Feb 3, 2026 |
| Jill Buck | Chief Development Officer | Feb 3, 2026 |
| Anthony Tzeyew Cheung | Chief Scientific Officer | Feb 3, 2026 |
| Constantine Chinoporos | Interim Chief Business Officer | Jul 22, 2026 |
| Joan Connolly | Chief Technology Officer | Feb 3, 2026 |
| Ronald Harold Wilfred Cooper | CEO & President | Feb 3, 2026 |
| D. Ryan Daws | Chief Financial Officer | Feb 3, 2026 |
| Lee Giguere | Chief Legal Ofc. and Corp Secy | Feb 3, 2026 |
| William Grossman | Interim Chief Medical Officer | Sep 24, 2026 |
| Alexander Julian Nichols | Chief Strategy & Ops. Ofc | Feb 3, 2026 |
| Kathleen P. Richton | SVP, Finance and Treasurer | Jul 22, 2026 |
| Hussein Sweiti | Chief Medical Officer | Oct 1, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 22, 2026 | William Grossman | Buy | 5,102 | $1.97 |
| Sep 22, 2026 | William Grossman | Buy | 5,102 | $1.97 |
| Sep 22, 2026 | William Grossman | Buy | 5,102 | $1.97 |
| Sep 22, 2026 | William Grossman | Buy | 5,102 | $1.97 |
ENGNW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Oct 31, 2025 | — | $-117.30M | 2.29 | $-99.24M |
| Oct 31, 2024 | — | $-55.14M | 1.46 | $-48.28M |
| Oct 31, 2023 | — | $-99.92M | 151.22 | $-24.74M |
| Oct 31, 2022 | — | $-24.46M | 44.30 | $-17.59M |
Latest balance sheet: total assets $288.32M, total liabilities $58.03M, cash $41.02M (as of Jul 31, 2026).
ENGNW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Sep 8, 2026 | 8-K Item 2.02 (results) | — |
| Jun 15, 2026 | 8-K Item 2.02 (results) | — |
| Mar 9, 2026 | 8-K Item 2.02 (results) | — |
| Dec 22, 2025 | 8-K Item 2.02 (results) | — |
| Sep 11, 2025 | 8-K Item 2.02 (results) | — |
| Jun 12, 2025 | 8-K Item 2.02 (results) | — |
| Mar 10, 2025 | 8-K Item 2.02 (results) | — |
| Dec 19, 2024 | 8-K Item 2.02 (results) | — |
| Sep 10, 2024 | 8-K Item 2.02 (results) | — |
| Jun 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
| Jan 29, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Biogen (BIIB)Halozyme Therapeutics (HALO)Vaxcyte (PCVX)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Space Exploration Technologies (SPCX)Tesla (TSLA)Sandisk (SNDK)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on ENGNW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 20, 2026, 1:16 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.